Özkan, GülsümUlusoy, ŞükrüErdem, YunusAltun, BülentYılmaz, RahmiAta, NaimBirinci, Şuayip2023-04-202023-04-2020221064-19631525-6006https://doi.org/10.1080/10641963.2022.2071923https://hdl.handle.net/20.500.11776/10832Aim The effect of hypertension (HT) and antihypertensive therapies such as renin-angiotensin-aldosterone system (RAAS) blockers on the disease course in COVID-19 patients is controversial. The purpose of this study was to evaluate the effect of HT and antihypertensive therapies on the course of COVID-19 disease. Method The age, sex, comorbid diseases, and antihypertensive therapies of 132,790 patients with positive COVID-19 real-time transcriptase polymerase chain reaction (RT-PCR) tests in the Turkish Health Ministry National COVID-19 database between 11 March and 31 May 2020, were examined and analyzed. Results Forty-one percent of the 132,790 patients in this study (median age: 40, 47.3% female) were hospitalized for treatment, and 4.5% were followed-up in the intensive care unit (ICU). The most frequent comorbid disease, at 19.5%, was HT (n = 25,863). Mortality was determined in 4.9% of HT patients and 1.9% of non-HT patients (p < .001). HT, age, and male gender emerged as independent predictors of hospitalization and admission to the ICU, while HT was not a predictor of mortality. In addition, no adverse effect of any antihypertensive treatment, including RAAS inhibitors, on mortality was detected. Conclusion Based on Turkish national data, HT is common in COVID-19 patients, but does not appear to be an independent predictor of mortality, and no adverse effect of RAAS inhibitors on COVID-19-related mortality was observed.en10.1080/10641963.2022.2071923info:eu-repo/semantics/closedAccessHypertensionCovid-19AntihypertensiveMortalityRaas BlockerOutcomesArticle446502506Q3WOS:0007911354000012-s2.0-8513263366235510709Q3